Skip to main content
. 2017 Dec;148:53–64. doi: 10.1016/j.antiviral.2017.10.015

Fig. 1.

Fig. 1

Binding characteristics of mAbs 2A5 and AP33. (A) mAbs 2A5 and AP33 were serially diluted and incubated on plates pre-coated with cell lysates containing HCV E1E2 derived from prototype isolates (H77c, JFH1, S52) and gt1b patient-derived viral isolates (P09_VA, P12_VA, P12_1091). Dose-dependent binding is expressed as percentage of maximal binding (mean ± standard deviation (error bars)). (B) EC50 values were calculated from dose-response curves shown in (A). All conditions were performed in duplicate.